Concepedia

Scott C. Jeffrey

SC

22

Publications

2.3K

Citations

17

H-Index

1996

Active since

Affiliations

Seagen (United States)(Current)

Fred Hutch Cancer Center

Oregon State University

Scott C. Jeffrey is an author at Seagen (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

1996–2020

22

Publications

22

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

Stephen C. Alley, Dennis R. Benjamin, Scott C. Jeffrey et al. · Bioconjugate Chemistry · 2008 · 456 citations

, , +18

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 381 citations

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 241 citations

, , +21

Development of orally active inhibitors of protein and cellular fucosylation

Nicole M. Okeley, Stephen C. Alley, Martha E. Anderson et al. · Proceedings of the National Academy of Sciences · 2013 · 183 citations · Full text

, , +21

Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates

Scott C. Jeffrey, Jamie B. Andreyka, Starr X. Bernhardt et al. · Bioconjugate Chemistry · 2006 · 166 citations

, , +16

Rows per page

1–5 of 22